Display options
Cite
Vallo S, Michaelis M, Gust KM, et al. Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. BMC Res Notes. 2016;9(1):454doi: 10.1186/s13104-016-2256-3.
Vallo, S., Michaelis, M., Gust, K. M., Black, P. C., Rothweiler, F., Kvasnicka, H. M., Blaheta, R. A., Brandt, M. P., Wezel, F., Haferkamp, A., & Cinatl, J. (2016). Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. BMC research notes, 9(1), 454. https://doi.org/10.1186/s13104-016-2256-3
Vallo, Stefan, et al. "Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts." BMC research notes vol. 9,1 (2016): 454. doi: https://doi.org/10.1186/s13104-016-2256-3
Vallo S, Michaelis M, Gust KM, Black PC, Rothweiler F, Kvasnicka HM, Blaheta RA, Brandt MP, Wezel F, Haferkamp A, Cinatl J. Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts. BMC Res Notes. 2016 Sep 27;9(1):454. doi: 10.1186/s13104-016-2256-3. PMID: 27677700; PMCID: PMC5039786.
Copy Download .nbib Format: NLM
Share it on

BMC Res Notes. 2016 Sep 27;9(1):454. doi: 10.1186/s13104-016-2256-3.

Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts.

BMC research notes

Stefan Vallo, Martin Michaelis, Kilian M Gust, Peter C Black, Florian Rothweiler, Hans-Michael Kvasnicka, Roman A Blaheta, Maximilian P Brandt, Felix Wezel, Axel Haferkamp, Jindrich Cinatl

Affiliations

  1. Institute of Medical Virology, Goethe University Frankfurt, Paul-Ehrlich-Str. 40, 60596, Frankfurt am Main, Germany.
  2. Department of Urology, Goethe University Frankfurt, Frankfurt, Germany.
  3. Centre for Molecular Processing and School of Biosciences, University of Kent, Canterbury, UK.
  4. Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.
  5. Dr. Senckenberg Institute of Pathology, Goethe University Frankfurt, Frankfurt am Main, Germany.
  6. Department of Urology, University Hospital Ulm, Ulm, Germany.
  7. Institute of Medical Virology, Goethe University Frankfurt, Paul-Ehrlich-Str. 40, 60596, Frankfurt am Main, Germany. [email protected].

PMID: 27677700 PMCID: PMC5039786 DOI: 10.1186/s13104-016-2256-3

Abstract

BACKGROUND: Systemic chemotherapy with gemcitabine and cisplatin is standard of care for patients with metastatic urothelial bladder cancer. However, resistance formation is common after initial response. The protein Src is known as a proto-oncogene, which is overexpressed in various human cancers. Since there are controversial reports about the role of Src in bladder cancer, we evaluated the efficacy of the Src kinase inhibitor dasatinib in the urothelial bladder cancer cell line RT112 and its gemcitabine-resistant sub-line RT112

METHODS: RT112 urothelial cancer cells were adapted to growth in the presence of 20 ng/ml gemcitabine (RT112

RESULTS: Dasatinib exerted similar effects on Src signaling in RT112 and RT112

CONCLUSION: Dasatinib should be considered with care for the treatment of urothelial cancer, in particular for therapy-refractory cases.

Keywords: Acquired resistance; Cancer cell line collection; Dasatinib; Gemcitabine; Orthotopic xenograft model; Urothelial bladder cancer

References

  1. Cell Death Dis. 2011 Dec 15;2:e243 - PubMed
  2. Cancer Res. 2011 Feb 1;71(3):832-41 - PubMed
  3. J Clin Oncol. 2012 Feb 10;30(5):507-12 - PubMed
  4. J Urol. 1995 Oct;154(4):1532-8 - PubMed
  5. Oncogene. 2002 Apr 4;21(15):2347-56 - PubMed
  6. PLoS One. 2013 May 24;8(5):e64181 - PubMed
  7. Stem Cell Res Ther. 2013 Oct 30;4(5):133 - PubMed
  8. Mol Cancer Ther. 2010 May;9(5):1128-35 - PubMed
  9. Biomaterials. 2014 Jan;35(1):71-82 - PubMed
  10. Mol Cancer Res. 2008 Nov;6(11):1766-74 - PubMed
  11. J Nucl Med. 2015 Mar;56(3):354-60 - PubMed
  12. Cancer Res. 2014 Dec 15;74(24):7217-28 - PubMed
  13. Expert Rev Anticancer Ther. 2008 Jan;8(1):51-61 - PubMed
  14. Cancer Prev Res (Phila). 2011 Oct;4(10):1698-709 - PubMed
  15. Transl Oncol. 2015 Jun;8(3):210-6 - PubMed
  16. PLoS One. 2012;7(11):e48929 - PubMed
  17. Mol Cancer Ther. 2013 Jul;12(7):1245-54 - PubMed
  18. Urol Oncol. 2016 Jan;34(1):4.e11-7 - PubMed
  19. Br J Cancer. 2009 Jul 7;101(1):38-47 - PubMed
  20. Cancer Treat Rev. 2006 Oct;32(6):456-70 - PubMed
  21. J Biol Chem. 2014 Apr 11;289(15):10900-8 - PubMed
  22. Int J Clin Exp Pathol. 2015 Jul 01;8(7):7818-24 - PubMed
  23. Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5807-12 - PubMed
  24. BJU Int. 2010 Dec;106(11):1799-804 - PubMed
  25. J Clin Oncol. 2005 Jul 20;23(21):4602-8 - PubMed
  26. Oncologist. 2014 Oct;19(10):1040-1 - PubMed
  27. BJU Int. 2007 Dec;100(6):1377-84 - PubMed
  28. Oncogene. 2000 Nov 20;19(49):5636-42 - PubMed

Publication Types